MedImmune, the global biologics research and development arm of AstraZeneca, and the University System of Maryland announced today that the initial research collaboration between MedImmune and the University of Maryland, Baltimore (UMB) has been expanded to include the University of Maryland, College Park and the University of Maryland, Baltimore County. The collaborators have also announced that they have identified the first five research projects to be undertaken under the expanded agreement. This follows the September 2013 announcement in which MedImmune and UMB announced a five-year, $6 million collaboration to drive novel bioscience research in the state of Maryland
{iframe}http://www.marketwatch.com/story/medimmune-expands-university-system-of-maryland-research-collaboration-2014-04-29{/iframe}